Ormany Soriano-Torres
Research Subjects
Research Interests
Ormany Soriano-Torres has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Abdel Bernal-Reyes
Department of Immunology, Instituto de Ciencias Básicas y Preclínicas “Victoria de Girón”, Universidad de Ciencias Médicas de La Habana, La Habana 10600, Cuba
1 shared publication - Alexis Labrada
BioCen, Mayabeque,La Habana,Cuba, Cuba
1 shared publication - Angel Alberto Justiz-Vaillant
Department of Pathology/Microbiology and Pharmacology. Faculty of Medical Sciences. The University of the West Indies.,St. Augustine.,Trinidad and Tobago, Trinidad and Tobago
1 shared publication - Belkis Romeu
Science Attache. Embassy of Cuba in Austria, Slovenia and Croatia, Nibelungengasse 11/19, 1010,Wienna,Austria, Austria
1 shared publication - Dainerys Aleida Pérez-Lastre
Curitiba,Paraná,Brazil, Brazil
1 shared publication - Dario Siniscalco
Experimental Medicine Department, “Luigi Vanvitelli” Campania University, 80138 Naples, Italy
1 shared publication
Latest Publications
- Open Access
- 30 October 2026
- Published by MDPI AG in Preprints.org
Overcoming Barriers to Mucosal Vaccination: From Adjuvant Concepts to Probiotic Spores and Cochleate as Innovative Approaches
Background. Mucosal vaccination offers the possibility of establishing immune protection directly at portals of pathogen entry, but its development remains constrained by biological, technological, and implementation barriers. Objective. To integrate the major challenges limiting mucosal vaccination within a common framework and examine emerging strategies capable of addressing several of these barriers simultaneously. Results and Discussion. We consider six interconnected challenges: incomplete recognition of the determinant role of adjuvants; scarcity of safe and accessible mucosal adjuvants; the need to overcome mucosal tolerance while preserving tissue homeostasis; dependence on coldchain logistics; reliance on multidose immunization schedules to achieve protective immunity; and limited breadth of vaccine-induced cross-reactive protection. To better capture the complexity of modern vaccine platforms, we discuss expand adjuvant activity as exogenous, self-adjuvanting, or endogenous according to the origin of the immunostimulatory signal. Particular emphasis is placed on proteoliposome- and cochleate-based systems and probiotic Bacillus subtilis spores as multifunctional platforms combining antigen delivery with intrinsic immunostimulatory properties. Preclinical studies support their capacity to induce systemic IgG, mucosal secretory IgA, cellular responses, and memory response, while their heat resistance may facilitate the development of more thermostable formulations. We also discuss the Single Time Vaccination Strategy as an approach to combined-route immunization and consider glycans and other microbial structures as potential contributors to antigen-specific and cross-reactive mucosal responses. Conclusions. Future mucosal vaccine development should consider adjuvants as tools for coordinated antigen delivery, innate sensing, immune programming with polarization activity, and mucosal memory rather than solely as immune potentiators and delivery system. Probiotic spores, cochleates, and combined-route strategies provide promising examples of this integrated approach, although their translational value will require rigorous demonstration of formulation stability, mechanisms of action, safety, protective breadth, and clinical efficacy.
- 30 October 2026
- Published by MDPI AG in Preprints.org
Open AccessOvercoming Barriers to Mucosal Vaccination: From Adjuvant Concepts to Probiotic Spores and Cochleate as Innovative Approaches
Background. Mucosal vaccination offers the possibility of establishing immune protection directly at portals of pathogen entry, but its development remains constrained by biological, technological, and implementation barriers. Objective. To integrate the major challenges limiting mucosal vaccination within a common framework and examine emerging strategies capable of addressing several of these barriers simultaneously. Results and Discussion. We consider six interconnected challenges: incomplete recognition of the determinant role of adjuvants; scarcity of safe and accessible mucosal adjuvants; the need to overcome mucosal tolerance while preserving tissue homeostasis; dependence on coldchain logistics; reliance on multidose immunization schedules to achieve protective immunity; and limited breadth of vaccine-induced cross-reactive protection. To better capture the complexity of modern vaccine platforms, we discuss expand adjuvant activity as exogenous, self-adjuvanting, or endogenous according to the origin of the immunostimulatory signal. Particular emphasis is placed on proteoliposome- and cochleate-based systems and probiotic Bacillus subtilis spores as multifunctional platforms combining antigen delivery with intrinsic immunostimulatory properties. Preclinical studies support their capacity to induce systemic IgG, mucosal secretory IgA, cellular responses, and memory response, while their heat resistance may facilitate the development of more thermostable formulations. We also discuss the Single Time Vaccination Strategy as an approach to combined-route immunization and consider glycans and other microbial structures as potential contributors to antigen-specific and cross-reactive mucosal responses. Conclusions. Future mucosal vaccine development should consider adjuvants as tools for coordinated antigen delivery, innate sensing, immune programming with polarization activity, and mucosal memory rather than solely as immune potentiators and delivery system. Probiotic spores, cochleates, and combined-route strategies provide promising examples of this integrated approach, although their translational value will require rigorous demonstration of formulation stability, mechanisms of action, safety, protective breadth, and clinical efficacy.
- Open Access
Neuroimmune Dysregulation and Synaptic Pruning in Autism Spectrum Disorder
Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by social communication deficits and repetitive behaviors, now affecting approximately 1 in 31 children. While traditionally defined behaviorally, ASD is increasingly understood as a disorder of brain connectivity arising from altered synaptic formation and refinement. This narrative review synthesizes evidence on neuroimmune dysregulation in ASD, focusing on immune-mediated synaptic pruning mechanisms. We conducted a comprehensive literature search in PubMed, Scopus, and Web of Science (2010–2026), prioritizing high-impact peer-reviewed research. Convergent findings suggest that the classical complement cascade (C1q-C3) tags specific synapses for elimination, while microglia participate in the phagocytic removal of tagged connections. Genetic studies have reported associations between ASD and variants in complement-related genes (C1q, C3, CR3, and C4A, although the strongest evidence for C4A-mediated pruning comes from schizophrenia research), as well as in microglial function genes (TREM2, PTEN, SHANK3). Neuroimaging reveals a dynamic pattern of local hyperconnectivity transitioning to long-range hypoconnectivity during development, particularly affecting prefrontal, insular, and cerebellar regions. Systemic inflammation, including gut–brain axis dysbiosis and maternal immune activation, may amplify neuroimmune dysregulation. We conclude that ASD can be understood, in part, as a disorder of synaptic immunology, where disrupted neuroimmune communication during critical developmental windows may contribute to altered connectivity. The complement–microglia axis therefore represents a potential mechanistic target for future therapeutic investigation.
Open AccessNeuroimmune Dysregulation and Synaptic Pruning in Autism Spectrum Disorder
Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by social communication deficits and repetitive behaviors, now affecting approximately 1 in 31 children. While traditionally defined behaviorally, ASD is increasingly understood as a disorder of brain connectivity arising from altered synaptic formation and refinement. This narrative review synthesizes evidence on neuroimmune dysregulation in ASD, focusing on immune-mediated synaptic pruning mechanisms. We conducted a comprehensive literature search in PubMed, Scopus, and Web of Science (2010–2026), prioritizing high-impact peer-reviewed research. Convergent findings suggest that the classical complement cascade (C1q-C3) tags specific synapses for elimination, while microglia participate in the phagocytic removal of tagged connections. Genetic studies have reported associations between ASD and variants in complement-related genes (C1q, C3, CR3, and C4A, although the strongest evidence for C4A-mediated pruning comes from schizophrenia research), as well as in microglial function genes (TREM2, PTEN, SHANK3). Neuroimaging reveals a dynamic pattern of local hyperconnectivity transitioning to long-range hypoconnectivity during development, particularly affecting prefrontal, insular, and cerebellar regions. Systemic inflammation, including gut–brain axis dysbiosis and maternal immune activation, may amplify neuroimmune dysregulation. We conclude that ASD can be understood, in part, as a disorder of synaptic immunology, where disrupted neuroimmune communication during critical developmental windows may contribute to altered connectivity. The complement–microglia axis therefore represents a potential mechanistic target for future therapeutic investigation.